Sanofi teams with vir­tu­al re­al­i­ty biotech on oral Dupix­ent suc­ces­sor

Sanofi’s lat­est bet on a po­ten­tial Dupix­ent se­quel is a pre­clin­i­cal pill de­vel­oped by a British small-cap that spe­cial­izes in vir­tu­al re­al­i­ty chem­istry.

The French phar­ma rolled the dice Mon­day on an up to $500 mil­lion deal with C4X Dis­cov­ery. The mile­stone-heavy, $8 mil­lion up­front agree­ment will li­cense to Sanofi a small mol­e­cule the dis­cov­ery biotech de­vel­oped to block the cy­tokine IL-17 — a po­ten­tial oral treat­ment for pso­ri­a­sis and oth­er in­flam­ma­to­ry con­di­tions.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER